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Abstract
Background: Non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutants have been shown to emerge after
interruption of suppressive NNRTI-based antiretroviral therapy (ART) using routine testing. The aim of this study was to
quantify the risk of resistance by sensitive testing and correlate the detection of resistance with NNRTI concentrations after
treatment interruption and virologic responses after treatment resumption.
Methods: Resistance-associated mutations (RAMs) and NNRTI concentrations were studied in plasma from 132 patients who
interrupted suppressive ART within SMART. RAMs were detected by Sanger sequencing, allele-specific PCR, and ultra-deep
sequencing. NNRTI concentrations were measured by sensitive high-performance liquid chromatography.
Results: Four weeks after NNRTI interruption, 19/31 (61.3%) and 34/39 (87.2%) patients showed measurable nevirapine
(.0.25 ng/ml) or efavirenz (.5 ng/ml) concentrations, respectively. Median eight weeks after interruption, 22/131 (16.8%)
patients showed$1 NNRTI-RAM, including eight patients with NNRTI-RAMs detected only by sensitive testing. The adjusted
odds ratio (OR) of NNRTI-RAM detection was 7.62 (95% confidence interval [CI] 1.52, 38.30; p = 0.01) with nevirapine or
efavirenz concentrations above vs. below the median measured in the study population. Staggered interruption, whereby
nucleos(t)ide reverse transcriptase inhibitors (NRTIs) were continued for median nine days after NNRTI interruption, did not
prevent NNRTI-RAMs, but increased detection of NRTI-RAMs (OR 4.25; 95% CI 1.02, 17.77; p = 0.03). After restarting NNRTI-
based ART (n = 90), virologic suppression rates,400 copies/ml were 8/13 (61.5%) with NNRTI-RAMs, 7/11 (63.6%) with NRTI-
RAMs only, and 51/59 (86.4%) without RAMs. The ORs of re-suppression were 0.18 (95% CI 0.03, 0.89) and 0.17 (95% CI 0.03,
1.15) for patients with NNRTI-RAMs or NRTI-RAMs only respectively vs. those without RAMs (p = 0.04).
Conclusions: Detection of resistant mutants in the rebound viremia after interruption of efavirenz- or nevirapine-based ART
affects outcomes once these drugs are restarted. Further studies are needed to determine RAM persistence in untreated
patients and impact on newer NNRTIs.
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Introduction
The SMART trial randomized HIV-1 infected patients with
CD4 counts .350 cells/mm3 to take antiretroviral therapy (ART)
either continuously or episodically, guided by the CD4 cell count
[1]. Results showed that interrupting treatment carried a
significant risk of morbidity and mortality. There remain
circumstances when ART discontinuation may be required (e.g.,
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due to toxicity), or may occur unplanned due to patient choice or
problems with drug supply (e.g., in resource-limited settings). In
patients receiving ART with agents that have different elimination
half-lives, simultaneous interruption of all drugs can lead to a
period of inadvertent monotherapy, which can result in viral
replication in the presence of a single drug, promoting selection of
drug-resistant mutants. This is expected to be a problem especially
with the non-nucleoside reverse transcriptase inhibitors (NNRTIs),
as they show the longest plasma half-lives among available
antiretrovirals [2]. NNRTI clearance rates show significant inter-
person variability, however, reflecting the activity of enzymes
responsible for NNRTI metabolism, which in turn are influenced
by multiple encoding and regulatory genes [3,4]. A low genetic
barrier to resistance further compounds the problem of stopping
NNRTI-based ART, as a single mutation in reverse transcriptase
(RT) is typically sufficient to abrogate drug activity [5]. It can
therefore be proposed that selection of NNRTI resistance may
occur in patients stopping NNRTI-based ART and that the risk is
higher the slower the NNRTI clearance rate. However, previous
studies investigating the correlation between NNRTI concentra-
tions after treatment interruption and detection of NNRTI
resistance have not been conclusive, possibly due to small numbers
and low sensitivity of testing methods [6,7]. The extent to which
treatment interruption leads to emergence of drug-resistant virus is
important for understanding the full implications of stopping ART
in relation to both subsequent treatment outcomes and risk of
transmission of drug-resistant HIV.
The risk of resistance after interruption of NNRTI-based ART
has been previously estimated using Sanger sequencing [6–9]. We
reported that among 141 patients who interrupted NNRTI-based
ART within SMART, 18 (13%) had evidence of NNRTI
resistance in the two months following interruption [8]. Sanger
sequencing fails to detect mutants present in the viral quasispecies
at a frequency below approximately 20%, suggesting that an even
greater proportion of patients may carry resistant mutants below
this detection limit. The issue is especially relevant to NNRTI
therapy. Low-frequency NNRTI-resistant mutants have been
detected in both ART-naive and NNRTI-experienced patients
with and without high-frequency mutants, and shown to impair
responses to NNRTI-based ART [10,11]. Recommended strate-
gies to minimize the potential risk of drug resistance after
interruption of NNRTI-based ART include stopping the NNRTI
first and continuing the remaining drugs in the regimen for a short
period, commonly the nucleos(t)ide RT inhibitors (NRTIs)
(staggered interruption), or replacing the NNRTI with a
ritonavir-boosted protease inhibitor (PI/r) for a short period
(switched interruption) [12]. There is limited evidence supporting
one particular strategy. In a previous study using Sanger
sequencing, no NNRTI-RAMs were detected in virologically
suppressed children that stopped nevirapine or efavirenz accord-
ing to either a staggered or a switched interruption modality [9].
Within SMART, we previously reported that both the detection of
drug resistance after interruption (by Sanger sequencing) and re-
suppression rates after restarting therapy were higher among
patients with staggered or switched interruption relative to those
with simultaneous interruption [8]. Expanding our previous
observations, the aim of this study was to obtain a more accurate
estimation of the risk of NNRTI resistance after interruption of
NNRTI-based ART by sensitive testing with allele-specific (AS)-
PCR and ultra-deep sequencing (UDS). We then investigated the
correlation between detection of NNRTI resistance and NNRTI
concentrations after treatment interruption, and analyzed the
findings in relation to virologic responses after resumption of
NNRTI-based ART.
Methods
Study Population
Eligible patients were receiving NNRTI-based ART, had a
plasma HIV-1 RNA load (‘viral load’) ,400 copies/ml, and were
randomized to the drug conservation arm of SMART and thus to
undergo a treatment interruption [1]. A total of 132/984 (13.4%)
patients who interrupted suppressive NNRTI-based ART in
SMART and had stored plasma samples available for testing
were included in this sub-study. The modality of interruption was
chosen by the treating physician, as previously described [8].
Therapy was re-started when the CD4 count decreased ,250
cells/mm3 or at the occurrence of clinical events [1].
Ethics Statement
The Institutional Review Board at the University of Minnesota
approved the proposal for the use of stored specimens. All
necessary permits were obtained for the described study, which
complied with all relevant regulations. The samples used in this
study have been described in previous publications (references 1
and 8).
Drug Concentrations
Efavirenz and nevirapine concentrations were measured by
validated [13,14], highly sensitive high-performance liquid chro-
matography (HPLC) in plasma samples collected at week 4 (visit 1)
after NNRTI interruption. The assay lower limit of quantification
was 0.25 ng/ml for nevirapine and 5 ng/ml for efavirenz.
Drug Resistance
Plasma samples collected 4–12 weeks after NNRTI interruption
were used for resistance testing. Selection was based upon sample
availability and viral load levels .3000 copies/ml to allow reliable
testing by the sensitive assays. Samples underwent Sanger
sequencing and AS-PCR as previously described [15–17]. The
AS-PCR targeted the NNRTI resistance-associated mutations
(RAMs) K103N, Y181C, and Y188L; samples showing K103N
were also tested for G190A. In addition samples were screened for
the presence of NRTI-RAMs, including thymidine analogue
mutations (TAMs), K65R, Q151M and M184V/I. Mutation-
specific interpretative cut-offs ranging from 0.3% to 1% were
applied as previously described [15]. In a subset of 21 samples,
UDS of the RT amino acid region 100 to 190 (RT100–190UDS) was
performed as previously described [18]; samples were selected
randomly from three subsets according to volume availability:
samples with RAMs by AS-PCR; samples without RAMs by AS-
PCR; and samples that failed the AS-PCR reaction. Briefly, viral
RNA was extracted from 500 ml of plasma (EasyMag, Biome´rieux,
France) and reverse transcribed into cDNA using the Accuscript
HF RT enzyme (Agilent, Santa Clara, USA) and random
hexamers. The RT region spanning amino acids 100 to 190 was
amplified by nested PCR, and pooled barcoded amplicons were
sequenced on the GS-FLX instrument (454 Life Sciences, Roche,
Branford, USA) according to the manufacturer’s standard
protocol. The experiment was designed to reach on average a
mutation detection sensitivity of 1% and an average coverage of
5,500 reads per position was obtained. Amplicons were sequenced
from both ends (forward and reverse). The Amplicon Variant
Analyzer (AVA) software (Roche) was used for read mapping and
calculating variant frequencies at each nucleotide position relative
to HIV-1 reference strain HXB2. The presence of relevant
mutations was manually verified by inspection of the individual
owgrams. A detection limit of 1% was chosen to avoid the high
probability of technical artifacts below this threshold [19]. Major
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RAMs were assigned according to the International IAS-USA list
(Nov 2011).
Statistical Analysis
Factors associated with the detection of RAMs by all testing
modalities combined (n = 131) were investigated using standard
univariable and multivariable logistic regression analysis. All
factors of interest were stipulated a priori and included in the
multivariable models. In the first model, the variables analyzed
were age, gender, ethnicity, HIV-1 transmission risk group, nadir
CD4 count, duration of ART before interruption, viral load and
CD4 count at the time of interruption, and interruption modality.
In a second model exploring factors associated with the detection
of NNRTI-RAMs, the analysis also included nevirapine and
efavirenz plasma concentrations (n = 70). To overcome the
limitation related to the small number of observations, the drug
concentration data were pooled and analyzed as categorical
variables (either above or below the median concentration
measured in the study population). This approach was stipulated
a priori as there was insufficient statistical power to analyze the two
drugs separately or assess the interaction between nevirapine and
efavirenz in this model. The proportion of patients who regained
virologic suppression ,400 copies/ml after re-starting NNRTI-
based ART was investigated using logistic regression analysis as an
intention-to-treat switch = failure analysis. Only patients restarting
ART without a PI and with at least one viral load measurement in
the following 4–12 months were included (n = 90). All factors of
interest were stipulated a priori and included in the multivariable
models. The variable included were age, gender, duration of ART
before interruption, viral load and CD4 count at the time of
interruption, time between interrupting and restarting ART, the
NNRTI restarted, the interruption modality and the presence of
RAMs. P-values were not corrected for multiple comparisons. All
statistical analyses were performed using STATA software
(StataCorp. 2007. Stata Statistical Software: Version 10.2/SE,
College Station, Texas, USA).
Results
Study Population
The analysis included 132 patients that interrupted efavirenz
(n = 80, 60.6%), nevirapine (n = 51, 38.6%), or delavirdine (n = 1,
0.8%) in SMART. All patients were also receiving $1 NRTI,
comprising lamivudine (n = 86, 65.1%), tenofovir (n = 55; 41.7%),
zidovudine (n = 48, 36.4%), emtricitabine (n = 22, 16.7%), abaca-
vir (n = 20; 15.1%), didanosine (n = 19; 14.4%), or stavudine
(n = 16, 12.1%). In addition, 15/132 (11.4%) patients were
receiving a PI. The modality of interruption was simultaneous in
63/132 (47.7%) patients, staggered in 46/132 (34.8%) patients,
and switched in 23/132 (17.4%) patients. The latter two groups
continued the NRTIs or replaced the NNRTI with a PI/r
respectively for median nine days (interquartile range, IQR 7, 14)
before stopping all therapy. The characteristics of the study
population at the time of NNRTI interruption and according to
the interruption modality are summarized in Table 1. At the time
of interruption all patients showed a viral load ,400 copies/ml.
Overall 113/132 (85.6%) patients had an ‘‘undetectable’’ viral
load, but the lower limit of quantification varied by site and was
,400 copies/ml in 30/132 (22.7%) patients, ,75 copies/ml in
16/132 (12.1%) patients, and ,50 copies/ml in 67/132 (50.8%)
patients. A further 19/132 (14.4%) patients had a viral load
between 50 and 400 copies/ml (median 175 copies/ml; range 55
to 394 copies/ml).
Drug Concentrations
NNRTI concentrations were measured in 70 patients with
sufficient plasma samples available at week 4, the first study visit
after NNRTI interruption. Median 32 days (IQR 27, 38) after
interruption, nevirapine was detected in 19/31 (61.3%) patients at
a median concentration of 2.2 ng/ml (IQR 1.0, 49). Median 30
days (IQR 27, 34) after interruption, efavirenz was detected in 34/
39 (87.2%) patients at a median concentration of 21 ng/ml (IQR
11, 61). Overall median concentrations (calculated by assigning a
value of zero to results below the assay cut-off) were 1.0 ng/ml for
nevirapine (n = 31) and 16 ng/ml for efavirenz (n = 39).
Drug Resistance
Resistance testing was performed in samples collected median 8
weeks (IQR 4, 11) after NNRTI discontinuation. At the time of
testing, the median viral load was 27,618 copies/ml (IQR 8,480,
76,200). Resistance results by were obtained in 131/132 (99.2%)
samples, comprising 122 Sanger sequencing results, 124 AS-PCR
results, and 21 RT100–190UDS results (Table 2). Overall, 116
samples had results by both Sanger sequencing and sensitive
resistance testing. Six samples failed the AS-PCR reaction and had
only Sanger sequencing results (including one sample with NRTI-
RAMs); two further samples failed the AS-PCR reaction and had
both Sanger sequencing results (including one sample with NRTI-
RAMs) and RT100–190UDS results (no RAMs detected). Nine
samples did not have sufficient volume and were tested only by
AS-PCR (no RAMs detected). One sample failed to give a result
by both Sanger sequencing and AS-PCR (RT100–190UDS not
done). Of the 21 samples tested by both AS-PCR and RT100–
190UDS, 21 yielded a result by RT100–190UDS and 19 yielded a
result by AS-PCR.
The prevalence of $1 NNRTI-RAM by all testing modalities
was 22/131 (16.8%) overall. Sensitive testing detected $1
NNRTI-RAM in 8/116 (6.9%) samples lacking NNRTI-RAMs
by Sanger sequencing, and also increased the number of NNRTI-
RAMs detected in each sample (Table 3). With 19 samples that
underwent both tests, RT100–190UDS confirmed the AS-PCR
results, with the exception of one sample that showed G190A by
RT100–190UDS but not by AS-PCR; the frequency of the G190A
mutant was 4% by RT100–190UDS. In addition RT100–190UDS
detected NNRTI-RAMs not targeted by AS-PCR, including
V179D, L100I, and K101E. Detection of NNRTI-RAMs
according to the interruption modality was 13/62 (21.0%) for
simultaneous interruption, 8/46 (17.4%) for staggered interrup-
tion, and 1/23 (4.3%) for switched interruption.
The prevalence of $1 NRTI-RAM by all testing modalities was
24/131 (18.3%) overall. The NRTI-RAMs comprised TAMs in
20/24 patients, with mean 2.4 TAMs per patient; M184I/V in
15/24 patients; K65R in 3/25 patients; and L74V in 1/25 patient.
Sensitive testing detected $1 NRTI-RAM in 2/116 (1.6%)
patients lacking NRTI-RAMs by Sanger sequencing. These
included K65R after simultaneous interruption of tenofovir,
didanosine, and efavirenz (viral load at interruption 357 copies/
ml), and K70R after staggered interruption of zidovudine/
lamivudine and efavirenz (viral load at interruption ,50 copies/
ml) (Table 3). Sensitive testing also detected additional NRTI-
RAMs in two samples already showing NRTI-RAMs by Sanger
sequencing (Table 3). With 19 samples that underwent both tests,
RT100–190UDS confirmed the AS-PCR results, with the exception
of one sample that showed M184V by RT100–190UDS but not by
AS-PCR; the frequency of the M184V mutant was 3% by RT100–
190UDS. Detection of NRTI-RAMs according to the interruption
modality was 10/62 (16.1%) for simultaneous interruption, 13/46
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(28.3%) for staggered interruption, and 1/23 (4.3%) for switched
interruption.
In total, 13/131 (9.9%), 9/131 (6.9%) and 15/131 (11.4%)
patients had $1 NNRTI-RAM, both NRTI-RAMs and NNRTI-
RAMs, and NRTI-RAMs only, respectively.
Predictors of Drug Resistance
Detection of NNRTI-RAMs was less likely in patients with a
viral load recorded as ,50 copies/ml at the time of treatment
interruption with an adjusted odds ratio (OR) of 0.28 (95%
confidence interval, CI 0.09, 0.91; p = 0.03) (Table 4). There was
also a trend towards a reduced risk of NNRTI-RAMs after a
switched interruption relative to a simultaneous interruption.
NNRTI-RAMs were detected in 10/31 (32.3%) patients with
week 4 NNRTI concentrations above the median level measured
in the study population (1 ng/ml for nevirapine and 16 ng/ml for
efavirenz), and 2/34 (5.9%) in patients with concentrations below
the median level (p = 0.007). A separate multivariable model was
used to assess the association between NNRTI-RAMs and drug
concentrations, to account for the fact that drug concentrations
were only available in 70 patients. In this analysis, NNRTI-RAM
detection was more likely in patients with NNRTI concentrations
above the median levels (.1 ng/ml for nevirapine and .16 ng/
ml for efavirenz) with an adjusted OR of 7.62 (95% CI 1.52,
38.30; p = 0.01). Detection of NRTI-RAMs was associated with
duration of ART exposure prior to interruption with an adjusted
OR of 1.26 for each year longer (95% CI 1.10, 1.45; p = 0.001);
the nadir CD4 count with an adjusted OR 0.68 for each 50 cells/
mm3 higher (95% CI 0.52, 0.87; p = 0.003); and staggered
interruption relative to simultaneous interruption with an adjusted
OR of 4.25 (95% CI 1.02, 17.77; p = 0.03).
Virologic Responses after Restarting NNRTI-based ART
Patients restarted ART median 29 weeks (IQR 13, 65) after
interruption. The analysis of responses was restricted to 90 patients
who restarted NNRTI-based ART (58 with efavirenz and 32 with
nevirapine) without a PI and had at least one viral load
measurement while on the NNRTI-based regimen in the 4–12
months after restarting. Overall, 73/90 (81.1%) patients regained
virologic suppression ,400 copies/ml; 50/90 (55.5%) had a viral
load recorded as ,50 copies/ml. The proportion of patients with
viral load,400 copies/ml was 8/13 (61.5%) with NNRTI-RAMs,
7/11 (63.6%) with NRTI-RAMs only, and 51/59 (86.4%) without
RAMs (p = 0.04); and 32/42 (76.2%), 23/29 (79.3%), and 18/19
(94.7%) following simultaneous, staggered, and switched interrup-
tion, respectively (p = 0.18). In multivariable analyses (Table 5), the
adjusted OR of suppression ,400 copies/ml was 0.18 (95% CI
Table 1. Characteristics of the study population that interrupted NNRTI-based ART in SMART, according to the interruption
modality.a
Total Interruption modality
Simultaneous Staggered Switched
n=132 n=63 n=46 n=23
Male gender, n (%) 99 (75.0) 47 (74.6) 32 (69.6) 20 (87.0)
Risk group, n (%) MSM 61 (46.2) 31 (49.2) 18 (39.1) 12 (57.2)
Heterosexual 41 (31.1) 20 (31.8) 18 (39.1) 3 (13.0)
Other/Unknown 30 (22.7) 12 (19.0) 10 (21.7) 8 (34.8)
Ethnicity, n (%) Black 51 (38.6) 22 (34.9) 21 (45.7) 8 (34.8)
White 63 (47.7) 34 (54.0) 18 (39.1) 11 (47.8)
Other/unknown 18 (13.6) 7 (11.1) 7 (15.2) 4 (17.4)
CDC category C, n (%) 31 (23.5) 11 (17.5) 13 (28.3) 7 (30.4)
HIV-1 RNA load ,50 copies/ml, n (%)b 67 (50.8) 26 (41.3) 29 (63.0) 12 (52.2)
Age, median years (IQR) 45 (39, 52) 44 (39, 50) 48 (41, 52) 45 (41, 54)
CD4 count, median cells/mm3 (IQR) 645 (475, 793) 624 (475, 833) 657 (461, 758) 643 (527, 751)
Nadir CD4 count, median cells/mm3 (IQR) 207 (90, 308) 212 (115, 374) 199 (67, 303) 205 (70, 300)
Time on ART, median years (IQR) 6 (3, 9) 6 (3, 9) 7 (3, 9) 6 (3, 10)
aPatients interrupted ART by simultaneously interrupting all drugs, continuing the nucleos(t)ide reverse transcriptase inhibitors (NRTIs) for a short period, or switching to
a ritonavir-boosted protease inhibitor for a short period, referred to as simultaneous, staggered and switched interruption respectively.
bIn 46 patients the viral load was measured by assays with a lower limit of quantification of either 75 or 400 copies/ml and results were ‘‘undetectable’’ below these cut-
offs; 19 patients showed a viral load between 50 and 400 copies/ml. NNRTI = non-nucleoside reverse transcriptase inhibitor; ART = antiretroviral therapy; MSM=Men
who have sex with men; IQR= interquartile range.
doi:10.1371/journal.pone.0069266.t001
Table 2. Summary of resistance results obtained by all
methodologies.a
Method Number
SS+AS-PCR 95
SS+AS-PCR+UDS 19
SS+UDS 2
SS only 6
AS-PCR only 9
None 1
Total 132
aPlasma samples underwent testing by Sanger sequencing (SS), allele-specific
PCR (AS-PCR) and ultra-deep sequencing (UDS) targeting mutations in HIV-1
reverse transcriptase.
doi:10.1371/journal.pone.0069266.t002
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0.03, 0.89) for patients with NNRTI-RAMs and 0.17 (95% CI
0.03, 1.15) for patients with NRTI-RAMs only, relative to patients
without RAMs (p = 0.04). The impact of the interruption modality
on likelihood of suppression ,400 copies/ml became more
evident 12–18 months after restarting ART, when the multivar-
iable model showed an adjusted OR of suppression ,400 copies/
ml of 10.01 for staggered/switched interruption relative to
simultaneous interruption (95% CI 1.73, 58.34; p = 0.01) (data
not shown).
Discussion
This study demonstrated RAMs in a substantial number of
patients experiencing rebound viremia after stopping suppressive
NNRTI-based ART. Interpretation of the findings should take
two limitations into consideration. Viral load assays with different
lower limits of quantification were used in SMART and viral load
suppression ,50 copies/ml could not be demonstrated in all
patients at study entry. Furthermore, due to sample availability,
NNRTI concentrations were obtained only in a subset of patients.
Nonetheless, the data provide sufficient evidence to indicate that
different factors influenced the detection of RAMs after ART
interruption. NNRTI-RAMs were less likely in patients who had a
viral load recorded as ,50 copies/ml at the time of interruption,
indicating a risk of selecting NNRTI resistance even at low levels
of viremia between 50 and 400 copies/ml. In addition, NNRTI-
RAMs were more likely in patients showing higher plasma
NNRTI concentrations at week 4 after interruption. These
findings provide support to the notion that selection of NNRTI
resistance can occur in patients experiencing slower NNRTI
clearance after ART interruption. Two previous studies did not
observe an association between NNRTI concentrations after
interruption and detection of NNRTI-RAMs [6,7]. One study
found that median efavirenz or nevirapine concentrations at day
15 after interruption did not differ significantly between 12
patients with NNRTI-RAMs (by Sanger sequencing) and 20
patients without RAMs [6]. Of note, the NNRTI was quantifiable
in less than a third of available samples. A second study reported
that median efavirenz concentrations and rate of efavirenz decline
over 7–10 days after interruption did not differ significantly
Table 3. Resistance-associated mutations in reverse transcriptase at week 8 after interruption of NNRTI-based ART, according to
the interruption modality, HIV-1 RNA load at interruption, and NNRTI concentrations at week 4 post-interruption.
Interruption
modality
Interrupted ART
regimen
Viral load
(copies/ml)
NNRTI
concentration
(ng/ml) Resistance-associated mutationsa
Simultaneous ZDV/3TC NVP 216 3.2 NNRTI: G190A
ZDV/3TC NVP ,400 ,0.25 NNRTI: Y181C
ZDV/3TC NVP ,50 1.0 NNRTI: K103N
TDF/FTC NVP ,50 1.3 NNRTI: K103N
TDF/FTC EFV ,50 16 NNRTI: K103N
TDF/FTC EFV ,75 64 NNRTI: Y188C
TDF 3TC NVP ,75 NA NNRTI: K103N (21) Y181C (6) G190A (4)
TDF 3TC NVP ,50 NA NNRTI: K101E Y181C G190S
D4T 3TC EFV ,75 41 NNRTI: V179D (10) Y188L (19); NRTI: M184V (15)
ABC 3TC EFV ,400 NA NNRTI: K103N; NRTI: L74V
TDF ZDV NVP ,50 NA NNRTI: K103N G190S
DDI NVP IDV ,400 .250 NNRTI: Y181C; NRTI: M41L D67E T69ins M184V L210W T215Y
TDF DDI EFV 357 NA NNRTI: L100I (6) K101E (2) K103N (98) G190A (14); NRTI: K65R
Staggered ZDV/3TC NVP ,400 49 NNRTI: L100I (3) K101E (8); NRTI : M41L D67N M184V (3) L210W T215Y
ZDV/3TC NVP ,50 1.6 NNRTI: Y181C; NRTI: M184V K219Q
ZDV/3TC EFV ,400 15 NNRTI: A98G K103N
ZDV/3TC EFV ,50 ,5 NNRTI: K103N (5) V179D (10); NRTI: K70R
DDI D4T NVP ,400 NA NNRTI: Y181C
DDI D4T EFV 238 67 NNRTI: K103N Y181C Y188L G190A; NRTI: Q151M M184I T215F
DDI NVP NFV 375 NA NNRTI: G190A
TDF EFV LPV/r ,75 NA NNRTI: G190EQR; NRTI: D67N T69A K70R T215F K219Q
Switched ZDV/3TC NVP ,50 0.6 NNRTI: K103N
Each row gives data for a single patient.
aResistance-associated mutations (RAMs) in reverse transcriptase (RT) were detected by Sanger sequencing, allele-specific PCR (AS-PCR) and ultra-deep sequencing
(UDS). AS-PCR targeted the NNRTI-RAMs K103N, Y181C, Y188L and G190A (the latter only in samples with K103N), and the following NRTI-RAMs: thymidine analogue
mutations (M41L, D67N, K70R, L210W, T215Y/F, K219Q), K65R, Q151M, and 184V/I. Mutation-specific cut-offs ranging between 0.3% and 1% were used for AS-PCR
interpretation as previously described [15]. UDS targeted the RT amino acid region 100–190; a detection limit of 1% was chosen to avoid the high probability of
technical artifacts below this threshold [19]. RAMs detected by sensitive testing but not by Sanger sequencing are indicated in bold; RAMs detected by RT100–190UDS but
not by AS-PCR are underlined; where RT100–190UDS results were obtained the frequency (%) of the mutant is given in brackets. Only samples with NNRTI-RAMs are
shown; an additional 15 samples had NRTI-RAMs only, without NNRTI-RAMs. NNRTI = non-nucleoside reverse transcriptase inhibitor; ART = antiretroviral therapy;
ZDV= zidovudine; 3TC = lamivudine; NVP = nevirapine; TDF= tenofovir; FTC = emtricitabine; EFV = efavirenz; D4T = stavudine; ABC= abacavir; DDI = didanosine;
IDV= indinavir; NFV= nelfinavir; LPV/r = lopinavir/ritonavir; NA= not available.
doi:10.1371/journal.pone.0069266.t003
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between 7 patients with NNRTI-RAMs (by Sanger sequencing)
and 14 patients without RAMs. Thus, both the size of the study
population, the timing of the assessment, and the sensitivity of the
testing methods for both drug concentrations and NNRTI-RAMs
differed in our study compared with the two previous reports. A
previous study of 19 patients receiving intermittent efavirenz-
based ART assayed efavirenz concentrations and used AS-PCR to
detect the NNRTI-RAM K103N during the off-therapy periods.
Consistent with our findings, AS-PCR increased detection of
NNRTI resistance relative to Sanger sequencing; furthermore the
half-life of efavirenz was higher in 8 patients in whom K103N
emerged compared with 11 patients in whom it did not (p = 0.04)
[20].
Genetic predictors of NNRTI clearance are being identified
which may help tailoring NNRTI discontinuation. The cyto-
chrome P450 (CYP)-2B6 isoenzyme (CYP2B6), for instance,
catalyzes the main oxidative metabolism reaction for efavirenz.
Three polymorphisms within the CYP2B6 gene have been
associated with efavirenz estimated Cmin, although together they
explain only one-third of inter-individual variability [4]. Mean-
while, measuring drug levels at week 4 after NNRTI discontin-
uation may potentially offer a readily available tool to assign
patients to the low or high risk of NNRTI-RAMs. It must be
pointed out however that the fact that drug concentrations were
measured in a subset of patients limits the power of our
conclusions. While the dataset was larger than in previous studies,
the statistical analysis required a separate model and pooling of the
nevirapine and efavirenz concentration data, which involved an
underlying assumption that the effect of nevirapine concentrations
is the same as that of efavirenz concentrations. The drug
concentration data were analyzed as categorical variables either
above or below the respective median concentrations measured in
the study population. Thus, the results provide proof-of principle
evidence that patients with slower nevirapine or efavirenz
clearance have a greater risk of NNRTI resistance after
interruption, although further studies are required to identify
drug-specific cut-offs that are predictive of resistance. Further
analyses of interest may also include the correlation between drug
concentrations measured before and after treatment interruption.
In addition, although we were unable to identify an association
between detection of NNRTI-RAMs and the NRTIs used (data
not shown), the different half-life of NRTIs has the potential to
influence the risk for resistance development [7] and its effects
warrant further investigation.
Detection of NRTI-RAMs was surprisingly common in this
study. NRTI-RAMs were more likely in patients with a long
previous ART history, suggesting re-emergence of resistant
mutants archived during previous virologic failures, rather than,
or in addition to, de novo selection during viral load rebound. In
support of this hypothesis, most NRTI-RAMs were detected by
Sanger sequencing, and there was a high prevalence of patients
showing two or more TAMs. As TAMs are known to emerge in
stepwise fashion during prolonged therapy with zidovudine or
stavudine [21], it would seem that multiple TAMs were unlikely to
arise for the first time solely as a result of treatment interruption.
Detailed treatment histories and results of previous resistance tests
would be required to corroborate this hypothesis. Interestingly,
there was an increased detection of NRTI-RAMs in patients with
a staggered interruption, suggesting a potential for selection or re-
selection of mutants by the continued NRTIs.
We previously reported that patients who had undergone a
simultaneous interruption showed reduced virologic responses
after restarting ART compared with those with a staggered or a
switched interruption [8]. Here we confirm the previous observa-
tion that simultaneous interruption should be avoided when
possible. We further propose that a switched interruption may be
Table 4. Predictors of detection of NNRTI resistance-associated mutations (RAMs) after interruption of NNRTI-based ART.a
Univariable analysis Multivariable analysis
OR 95% CI P-value OR 95% CI P-value
Gender Female 1.14 0.38, 3.49 0.81 0.83 0.16, 4.31 0.83
Male 1.00 – 1.00 –
Age Each 5 years older 1.00 0.78, 1.30 0.97 0.99 0.72, 1.37 0.95
Ethnicity White 0.48 0.17, 1.30 0.13 0.41 0.11, 1.46 0.20
Other/Unknown 0.19 0.02, 1.63 0.18 0.02, 1.75
Black 1.00 – 1.00
Risk group Heterosexual 0.94 0.29, 3.07 0.78 0.54 0.10, 2.85 0.48
Other/Unknown 0.68 0.08, 6.12 0.43 0.04, 4.52
MSM 1.00 –
Nadir CD4 count Each 50 cells/mm3 higher 0.94 0.81, 1.10 0.47 1.01 0.83, 1.23 0.91
Time on ART pre-interruption Each year longer 1.03 0.93, 1.15 0.54 1.05 0.91, 1.20 0.49
HIV-1 RNA load at interruptionb ,50 copies/ml 0.34 0.12, 0.95 0.04 0.28 0.09, 0.91 0.03
Other 1.00 – 1.00 –
CD4 count at interruption Each 50 cells/mm3 higher 0.94 0.83, 1.05 0.28 0.93 0.81, 1.08 0.35
Interruption modality Staggered 0.71 0.25, 1.98 0.17 0.80 0.23, 2.74 0.20
Switched 0.19 0.02, 1.54 0.11 0.01, 1.10 0.17
Simultaneous 1.00 – 1.00 –
aDetection of NNRTI-RAMs by all testing modalities. NNRTI concentrations were analyzed in a separate model due to smaller numbers.
bAs noted above some patients had the viral load measured by assays with a lower limit of quantification of either 75 or 400 copies/ml. NNRTI = non-nucleoside reverse
transcriptase inhibitor; ART = antiretroviral therapy; OR =Odds ratio; CI = confidence interval; MSM=Men who have sex with men.
doi:10.1371/journal.pone.0069266.t004
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preferable to a staggered interruption both to offer improved
protection against emergence of NNRTI-RAMs and reduce
selection of NRTI resistance; the latter may be especially
important in patients with previous NRTI experience.
In our previous study we used Sanger sequencing to detect
RAMs after ART interruption [8]. Here we demonstrated that
sensitive testing increased prevalence and spectrum of NNRTI-
RAMs detected during viral load rebound. The data provide a
measure of the potential risk of NNRTI resistance after ART
interruption. It should be noted that at 16.8%, the overall
prevalence of NNRTI-RAMs was lower than that observed in
patients either failing NNRTI-based ART or receiving single-dose
nevirapine for the prevention of mother to child transmission
[10,22]. This may be explained by the consideration that both
sufficient levels of virus replication and sufficient drug concentra-
tions must co-exist to allow selection of drug resistance. The
optimal ‘‘selection window’’ is likely to be narrower in patients
stopping NNRTI-based ART with a suppressed viral load relative
to patients receiving single-dose nevirapine in the presence of a
fully replicating virus. A further consideration is that patients
interrupting NNRTI-based ART in SMART had already
achieved steady-state NNRTI pharmacokinetics through the
induction of hepatic enzymes. In addition, testing samples
collected several weeks after treatment interruption, while required
to ensure adequate viral load levels, may have missed the earlier
emergence of resistant strains. Finally, the AS-PCR method
applies strict cut-offs for interpreting positivity.
The AS-PCR methodology employed in this study has
undergone extensive validation [15–17]. In previous studies we
demonstrated that low-frequency NNRTI-RAMs detected by AS-
PCR were predictive of virologic failure among naive patients
starting first-line NNRTI-based ART [11,16,17], and also
influenced the detection probability and type of NNRTI-RAMs
detected at the time of virologic failure [23]. One downside of AS-
PCR is that it is mutation-specific and to a large extent clade-
specific, and labor-intensive. In recent years, next-generation
sequencing methodologies, including UDS, have become available
that allow the quantitative detection of mutants with greatly
enhanced sensitivity relative to Sanger sequencing (reliably down
to a cut-off of about 1%) [19]. Direct comparisons of AS-PCR with
UDS are limited. A previous study of 11 samples undergoing AS-
PCR for K103N showed a good level of agreement with UDS
[20]. Here, using a subset of 21 samples that underwent both AS-
PCR and UDS, we found good concordance between the two
techniques at the respective validated cut-offs for interpretation.
Importantly, although the AS-PCR targeted a relatively small
number of NNRTI-RAMs, these were the key RAMs associated
with resistance to efavirenz or nevirapine, and the spectrum was
only marginally expanded in the samples that also underwent
UDS of the RT region spanning amino acids 100 to 190.
In summary, this study provides substantive evidence in support
of the widely cited hypothesis that stopping NNRTI-based ART
carries a risk of drug resistance. We show that viral load levels at
the time of interruption, plasma NNRTI concentrations at week 4
after interruption, overall treatment history, and interruption
modality combine to influence the risk of resistance and ultimately
predict virologic responses when NNRTI-based ART is resumed.
Further studies are required to assess the persistence of NNRTI-
RAMs in patients remaining off therapy, the potential for their
onward transmission, and the implication of these findings for
etravirine and rilpivirine use.
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Table 5. Predictors of virologic suppression ,400 copies/ml 4–12 months after restarting NNRTI-based ART.a
Univariable analysis Multivariable analysis
OR 95% CI P-value OR 95% CI P-value
Gender Female 0.60 0.19, 1.85 0.38 0.41 0.10, 1.68 0.22
Male 1.00 – 1.00 –
Age Each 5 years older 1.04 0.78, 1.39 0.79 1.09 0.71, 1.68 0.70
Time on ART pre-interruption Each year longer 0.91 0.80, 1.03 0.15 0.89 0.75, 1.07 0.21
HIV-1 RNA load at interruptionb ,50 copies/ml 1.09 0.38, 3.15 0.87 1.00 0.27, 3.72 0.99
Other 1.00 – 1.00 –
CD4 count at interruption Each 50 cells/mm3 higher 1.05 0.91, 1.19 0.52 1.06 0.89, 1.27 0.50
Time to restarting ART Each week longer 1.01 0.99, 1.04 0.21 1.02 0.99, 1.06 0.11
NNRTI restarted Nevirapine 0.55 0.19, 1.61 0.28 0.55 0.15, 2.09 0.38
Efavirenz 1.00 – 1.00 –
Interruption modality Staggered/Switched 1.83 0.63, 5.34 0.27 2.62 0.60, 11.38 0.20
Simultaneous 1.00 – 2.62 – 0.20
Resistance-associated mutations NNRTI 0.22 0.06, 0.84 0.03 0.18 0.03, 0.89 0.04
NRTI only 0.24 0.06, 1.01 0.17 0.03, 1.15
None 1.00 – 1.00 –
aThe analysis included 90 patients who restarted NNRTI-based ART without a protease inhibitor and had at least one viral load measurement in the 4–12 months after
re-starting therapy.
bAs noted above some patients had the viral load measured by assays with a lower limit of quantification of either 75 or 400 copies/ml. NNRTI = non-nucleoside reverse
transcriptase inhibitor; ART = antiretroviral therapy; OR =Odds ratio; CI = confidence interval.
doi:10.1371/journal.pone.0069266.t005
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